10/551182

Atty. Dkt. No. 081356-0251

JC20 RSC 0 PCT/PTU 2 9 SEP 2005

Takashi ISHIHARA

Applicant:

PURIFICATION OF HUMAN MONOCLONAL

ANTIBODY AND HUMAN POLYCLONAL ANTIBODY

Int'l. Appln. No.

Io. PCT/JP2004/003425

Int'l. Filing Date:

March 15, 2004

Examiner:

Unassigned

Art Unit:

Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Atty. Dkt. No. 081356-0251

JC20 Rec'd PCT/PTO 2 9 SEP 2005

RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. A copy of the cited references listed in the Search Report is not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date: 29 September 2005

FOLEY & LARDNER LLP Customer Number: 22428 Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent Attorney for Applicant Registration No. 29,768

JC20 Rec'd PCT/PTO 2 9 SER 2003 (08-00)
Approved for use through 10/31/2002. 0MB 0651-0031

Approved for use through 10/31/2002. OMB 0651-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paper	work Reduction Act of 1995, no	persons a	are required to respond t	o a collection of information unless it contai	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ns a valid OMB control number.			
	Substitute for form 1	449B/PT	0		Complete if Known 1551182			
	INFORMATION DIS	CLOSUR	E	Application Number	Unassigned 10/991106			
STATEMENT BY APPLICANT Date Submitted: September 29, 2005				Filing Date	September 29, 2005			
				First Named Inventor	Takashi ISHIHARA			
	vate Submitted: Septen	10er 29,	2005	Group Art Unit	Unassigned			
(use as many sheets as necessary)				Examiner Name	Unassigned			
Sheet	1	of	1	Attorney Docket Number	081356-0251			

Date of Publication of Pages, Columns, Lines, Wh					
	of Patentee or Applicant of Cited	U.S. Patent Document		Cite	Examiner
Gited Document Passages or Heler MM-DD-YYYY Figures Appea	Document ·	Kind Code ² (if known)	Number	No.1	Initials*
			·		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Do Office ³ Number ⁴	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6		
	-A1	# 3-310760 A		Ton Gosci Chem. Ind. Ltd.	11/22/1993				
/D.S	/ A2	WO 99/64462 A1		Statens Serum Institute	12/16/1999				
/D.S./		WO 01/64711 A1		Kyowa Hakko Kogyo Co., Ltd.	9/7/2001				
/D.S.		WO 96/33208 A1	10 5 /	Genentech, Inc.	10/24/1996				
			/D.S./						

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(5), volume-issue number(9), publisher, city and/or country where published.	1e
	A5	. R.I. Moellering et al., "Separating clinical oracle chimeric antibodies from serum derived immunoglobulins", BioPharm (1990) 3(1): pp. 34-38.	
		particularly, Table 1, Materials & Methods.	
	A6	H. Leibl, et al., "Separation of polysaccharide-specific human immunoglobulin G subclasses using a protein A superose column with a pH	
		gradient eutlion system , Journal of Chromatography, June 4, 1993, 639(1); pp. 51-56, particularly rigs. 1-4; table 1.	
			\vdash
			_
			┼
ł			
I			

Examiner	/David Saunders/	Date	05/08/2008
Signature		Considered	i e

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ¹⁸ if possible. ⁵Applicant is to place a check mark here if

English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. P.O. Box 1450.

Alexandria, V.A 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450.

Alexandria, V.A 22313-1450.